D. Ferrazzoli and P. Ortelli have contributed equally to this work.
A correction to this article is available online at https://doi.org/10.1007/s00415-018-9000-y.
Dopamine Replacement Therapy (DRT) represents the most effective treatment for Parkinson’s disease (PD). Nevertheless, several symptoms are unresponsive to treatment and its long-term use leads to serious side effects. To optimize the pharmacological management of PD, dopamine-agonists are often prescribed to “de-novo” patients. Moreover, several studies have shown the effectiveness and the synergic effect of rehabilitation in treating PD.
To evaluate the synergism between DRT and rehabilitation in treating PD, by investigating the short and the long-term effectiveness of a multidisciplinary, intensive and goal-based rehabilitation treatment (MIRT) in a group of patients treated with Rotigotine.
In this multicenter, single blinded, parallel-group, 1:1 allocation ratio, randomized, non-inferiority trial, 36 “de-novo” PD patients were evaluated along 18 months: 17 were treated with Rotigotine plus MIRT; 19 were treated with Rotigotine alone (R). The primary outcome measure was the total score of Unified Parkinson’s Disease Rating Scale (UPDRS). The secondary outcomes included the UPDRS sub-sections II and III (UPDRS II-III), the 6-Minute Walk Test (6MWT), the Timed Up and Go Test (TUG) and the amount of Rotigotine. Patients were evaluated at baseline (T0), 6 months (T1), 1 year (T2), and at 18 months (T3).
No differences in UPDRS scores in the two groups (total score, III part and II part, p = 0.48, p = 0.90 and p = 0.40, respectively) were found in the time course. Conversely, a greater improvement in Rotigotine + MIRT group was observed for 6MWT (p < 0.0001) and TUG (p = 0.03). Along time, the dosage of Rotigotine was higher in patients who did not undergo MIRT, at all observation times following T0.
Over the course of 18 months, the effectiveness of the combined treatment (Rotigotine + MIRT) on the patients’ global clinical status, evaluated with total UPDRS, was not inferior to that of the pharmacological treatment with Rotigotine alone. Importantly, rehabilitation allowed patients to gain better motor performances with lower DRT dosage.
Calabresi P, Ghiglieri V, Mazzocchetti P, Corbelli I, Picconi B (2015) Levodopa-induced plasticity: a double-edged sword in Parkinson’s disease? Philos Trans R Soc Lond B Biol Sci 370(1672). https://doi.org/10.1098/rstb.2014.0184 ( pii: 20140184)
Nishijima H, Suzuki S, Kon T, Funamizu Y, Ueno T, Haga R, Suzuki C, Arai A, Kimura T, Suzuki C, Meguro R, Miki Y, Yamada J, Migita K, Ichinohe N, Ueno S, Baba M, Tomiyama M (2014) Morphologic changes of dendritic spines of striatal neurons in the levodopa-induced dyskinesia model. Mov Disord 29:336–343. https://doi.org/10.1002/mds.25826 CrossRefPubMed
Stowe RL, Ives NJ, Clarke C, van Hilten J, Ferreira J, Hawker RJ, Shah L, Wheatley K, Gray R (2008) Dopamine agonist therapy in early Parkinson’s disease. Cochrane Database Syst Rev 2:CD006564. https://doi.org/10.1002/14651858.cd006564.pub2 CrossRef
Antonini A, Bernardi L, Calandrella D, Mancini F, Plebani M (2010) Rotigotine transdermal patch in the management of Parkinson’s disease (PD) and its night-time use for PD-related sleep disorders. Funct Neurol 25:21–25 PubMed
Tomlinson CL, Patel S, Meek C, Herd CP, Clarke CE, Stowe R, Shah L, Sackley CM, Deane KH, Wheatley K, Ives N (2013) Physiotherapy versus placebo or no intervention in Parkinson’s disease. Cochrane Database Syst Rev 9:CD002817. https://doi.org/10.1002/14651858.cd002817.pub4 CrossRef
Frazzitta G, Bertotti G, Riboldazzi G, Turla M, Uccellini D, Boveri N, Guaglio G, Perini M, Comi C, Balbi P, Maestri R (2012) Effectiveness of intensive inpatient rehabilitation treatment on disease progression in parkinsonian patients: a randomized controlled trial with 1-year follow-up. Neurorehabil Neural Repair 26:144–150. https://doi.org/10.1177/1545968311416990 CrossRefPubMed
Frazzitta G, Maestri R, Bertotti G, Riboldazzi G, Boveri N, Perini M, Uccellini D, Turla M, Comi C, Pezzoli G, Ghilardi MF (2015) Intensive rehabilitation treatment in early Parkinson’s disease: a randomized pilot study with a 2-year follow-up. Neurorehabil Neural Repair 29:123–131. https://doi.org/10.1177/1545968314542981 CrossRefPubMed
Ekker MS, Janssen S, Nonnekes J, Bloem BR, de Vries N (2016) Neurorehabilitation for Parkinson’s disease: future perspectives for behavioural adaptation. Parkinsonism Relat Disord 22(Suppl 1):73–77. https://doi.org/10.1016/j.parkreldis.2015.08.031 CrossRef
Canning CG, Sherrington C, Lord SR, Close JC, Heritier S, Heller GZ, Howard K, Allen NE, Latt MD, Murray SM, O’Rourke SD, Paul SS, Song J, Fung VS (2015) Exercise for falls prevention in Parkinson disease: a randomized controlled trial. Neurology 84:304–312. https://doi.org/10.1212/WNL.0000000000001155 CrossRefPubMedPubMedCentral
Petzinger GM, Fisher BE, Van Leeuwen JE, Vukovic M, Akopian G, Meshul CK, Holschneider DP, Nacca A, Walsh JP, Jakowec MW (2010) Enhancing neuroplasticity in the basal ganglia: the role of exercise in Parkinson’s disease. Mov Disord 25(Suppl 1):S141–S145. https://doi.org/10.1002/mds.22782 CrossRefPubMedPubMedCentral
Petzinger GM, Fisher BE, McEwen S, Beeler JA, Walsh JP, Jakowec MW (2013) Exercise-enhanced neuroplasticity targeting motor and cognitive circuitry in Parkinson’s disease. Lancet Neurol 12:716–726. https://doi.org/10.1016/S1474-4422(13)70123-6 CrossRefPubMedPubMedCentral
Fontanesi C, Kvint S, Frazzitta G, Bera R, Ferrazzoli D, Di Rocco A, Rebholz H, Friedman E, Pezzoli G, Quartarone A, Wang HY, Ghilardi MF (2016) Intensive rehabilitation enhances lymphocyte BDNF-TrkB signaling in patients with Parkinson’s disease. Neurorehabil Neural Repair 30:411–418. https://doi.org/10.1177/1545968315600272 CrossRefPubMed
Fisher BE, Wu AD, Salem GJ, Song J, Lin CH, Yip J, Cen S, Gordon J, Jakowec M, Petzinger G (2008) The effect of exercise training in improving motor performance and corticomotor excitability in people with early Parkinson’s disease. Arch Phys Med Rehabil 89:1221–1229. https://doi.org/10.1016/j.apmr.2008.01.013 CrossRefPubMedPubMedCentral
Ferrazzoli D, Carter A, Ustun FS, Palamara G, Ortelli P, Maestri R, Yücel M, Frazzitta G (2016) Dopamine replacement therapy, learning and reward prediction in Parkinson’s disease: implications for rehabilitation. Front Behav Neurosci 10:121. https://doi.org/10.3389/fnbeh.2016.00121 CrossRefPubMedPubMedCentral
Shulman LM, Gruber-Baldini AL, Anderson KE, Fishman PS, Reich SG, Weiner WJ (2010) The clinically important difference on the unified Parkinson’s disease rating scale. Arch Neurol 67:64–70. https://doi.org/10.1001/archneurol.2009.295 CrossRefPubMed
Frazzitta G, Maestri R, Uccellini D, Bertotti G, Abelli P (2009) Rehabilitation treatment of gait in patients with Parkinson’s disease with freezing: a comparison between two physical therapy protocols using visual and auditory cues with or without treadmill training. Mov Disord 24:1139–1143. https://doi.org/10.1002/mds.22491 CrossRefPubMed
Steffen T, Seney M (2008) Test-retest reliability and minimal detectable change on balance and ambulation tests, the 36-item short-form health survey, and the unified Parkinson disease rating scale in people with parkinsonism. Phys Ther 88:733–746. https://doi.org/10.2522/ptj.20070214 CrossRefPubMed
Ganesan M, Pal PK, Gupta A, Sathyaprabha TN (2010) Dynamic posturography in evaluation of balance in patients of Parkinson’s disease with normal pull test: concept of a diagonal pull test. Parkinsonism Relat Disord 16:595–599. https://doi.org/10.1016/j.parkreldis.2010.08.005 CrossRefPubMed
Ferrazzoli D, Fasano A, Maestri R, Bera R, Palamara G, Ghilardi MF, Pezzoli G, Frazzitta G (2015) Balance dysfunction in Parkinson’s disease: the role of posturography in developing a rehabilitation program. Parkinsons Dis 2015:520128. https://doi.org/10.1155/2015/520128 PubMedPubMedCentralCrossRef
Christiansen C, Moore C, Schenkman M, Kluger B, Kohrt W, Delitto A, Berman B, Hall D, Josbeno D, Poon C, Robichaud J, Wellington T, Jain S, Comella C, Corcos D, Melanson E (2017) Factors associated with ambulatory activity in de novo Parkinson disease. J Neurol Phys Ther 41:93–100. https://doi.org/10.1097/NPT.0000000000000169 CrossRefPubMedPubMedCentral
Schenkman M, Moore CG, Kohrt WM, Hall DA, Delitto A, Comella CL, Josbeno DA, Christiansen CL, Berman BD, Kluger BM, Melanson EL, Jain S, Robichaud JA, Poon C, Corcos DM (2017) Effect of high-intensity treadmill exercise on motor symptoms in patients with de novo Parkinson disease: a phase 2 randomized clinical trial. JAMA Neurol. https://doi.org/10.1001/jamaneurol.2017.3517 (Epub ahead of print) CrossRef
Moore CG, Schenkman M, Kohrt WM, Delitto A, Hall DA, Corcos D (2013) Study in Parkinson disease of exercise (SPARX): translating high-intensity exercise from animals to humans. Contemp Clin Trial 36:90–98. https://doi.org/10.1016/j.cct.2013.06.002 CrossRef
Ferrazzoli D, Ortelli P, Zivi I, Cian V, Urso E, Ghilardi MF, Maestri R, Frazzitta G (2018) Efficacy of intensive multidisciplinary rehabilitation in Parkinson’s disease: a randomised controlled study. J Neurol Neurosurg Psychiatry. https://doi.org/10.1136/jnnp-2017-316437 (pii: jnnp-2017-316437) PubMedCrossRef
Ferrazzoli D, Ortelli P, Maestri R, Bera R, Gargantini R, Palamara G, Zarucchi M, Giladi N, Frazzitta G (2017) Focused and sustained attention is modified by a goal-based rehabilitation in Parkinsonian patients. Front Behav Neurosci 11:56. https://doi.org/10.3389/fnbeh.2017.00056 CrossRefPubMedPubMedCentral
Hirsch MA, Iyer SS, Sanjak M (2016) Exercise-induced neuroplasticity in human Parkinson’s disease: what is the evidence telling us? Parkinsonism Relat Disord 22(Suppl 1):S78–S81. https://doi.org/10.1016/j.parkreldis.2015.09.030 CrossRefPubMed
Fisher BE, Li Q, Nacca A, Salem GJ, Song J, Yip J, Hui JS, Jakowec MW, Petzinger GM (2013) Treadmill exercise elevates striatal dopamine D2 receptor binding potential in patients with early Parkinson’s disease. NeuroReport 24:509–514. https://doi.org/10.1097/WNR.0b013e328361dc13 CrossRefPubMed
Petzinger GM, Walsh JP, Akopian G, Hogg E, Abernathy A, Arevalo P, Turnquist P, Vucković M, Fisher BE, Togasaki DM, Jakowec MW (2007) Effects of treadmill exercise on dopaminergic transmission in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned mouse model of basal ganglia injury. J Neurosci 27:5291–5300 CrossRefPubMed
Ferrazzoli D, Carter A, Ustun FS, Palamara G, Ortelli P, Maestri R, Yücel M, Frazzitta G (2016) Dopamine replacement therapy, learning and reward prediction in Parkinson’s Disease: implications for rehabilitation. Front Behav Neurosci 10:121. https://doi.org/10.3389/fnbeh.2016.00121 CrossRefPubMedPubMedCentral
de la Fuente-Fernández R (2009) The placebo-reward hypothesis: dopamine and the placebo effect. Parkinsonism Relat Disord 15(Suppl 3):S72–S74. https://doi.org/10.1016/S1353-8020(09)70785-0 CrossRefPubMed
- Effectiveness of Rotigotine plus intensive and goal-based rehabilitation versus Rotigotine alone in “de-novo” Parkinsonian subjects: a randomized controlled trial with 18-month follow-up
- Springer Berlin Heidelberg